Endocrinology Virtual Staffing: CGM and Insulin Prior Auth, A1C Recall, and Thyroid Workups

An endocrinology practice runs a high-volume diabetes panel layered on top of a thyroid, adrenal, pituitary, and metabolic bone workload. The administrative work is dominated by drug and device prior authorization for CGMs, insulin pumps, GLP-1s, and the rapidly expanding obesity-drug category. Layered on top is the A1C recall pipeline for the diabetes panel, the thyroid workup scheduling for new nodule and Graves' referrals, and the diabetes education coordination that keeps patients adherent.

A specialty-trained virtual endocrinology pod takes all four workflows off the practice's plate so the providers can spend visits on the clinical conversation rather than on payer paperwork.

CGM and insulin pump prior authorization

Continuous glucose monitor authorization is its own clinical discipline. Each payer publishes specific coverage criteria: type 1 versus type 2, insulin use threshold, A1C threshold, documented hypoglycemia, and the prior glucose log documentation. Dexcom, FreeStyle Libre, and Medtronic CGM systems each carry their own DME pathway with specific HCPCS codes and supplier networks.

Insulin pump authorization is even tighter: documented insulin regimen failure, motivation and training documentation, and the pump-specific clinical justification. A virtual endocrinology authorization specialist runs both queues, drafts the medical necessity letter, and routes to the correct DME supplier rather than letting the order sit in the chart for two weeks.

GLP-1 and obesity drug authorization

GLP-1 prior authorization has become a daily workload in endocrinology. Semaglutide, tirzepatide, dulaglutide, and the obesity-indication versions of each carry payer-specific BMI thresholds, comorbidity requirements, prior therapy documentation, and step-therapy ladders that change frequently. The supply situation has stabilized but the authorization rules have not.

A virtual authorization specialist tracks each payer's current GLP-1 policy, runs the daily queue, drafts the medical necessity letter, and handles the formulary alternatives conversation when the payer denies the requested product but approves a similar one. The same coordinator manages the patient-assistance program enrollment for patients whose coverage falls short.

A1C recall outreach for the diabetes panel

Every diabetes panel decays without active recall. Patients miss A1C labs, slip out of the visit cadence, and re-enter care months later with uncontrolled disease. The fix is a dedicated A1C recall coordinator who owns the registry, pulls the overdue list weekly, and runs multi-touch outreach across text, call, and portal until the patient either schedules or actively declines.

A virtual recall coordinator also owns the annual diabetic eye exam recall, the foot exam scheduling, and the urine microalbumin recall. These are the same outreach workflows that drive HEDIS and Medicare Stars performance for the diabetes panel, which directly affects payer bonus payments to value-based contracts.

Thyroid workup scheduling and the new-nodule pipeline

Every new thyroid nodule referral triggers a workup pipeline: ultrasound, possible fine-needle aspiration, lab panel, and the follow-up visit scheduling. Without a dedicated owner the workup stretches over weeks because nobody is sequencing the steps.

A virtual scheduling coordinator owns the new-referral intake, sequences the ultrasound and FNA with the practice's preferred radiology and pathology partners, and schedules the follow-up visit before the patient leaves the initial consultation. The same coordinator runs the Graves' disease workup pipeline and the routine TSH recall for patients on levothyroxine.

What an endocrinology virtual pod usually looks like

A typical two-to-four provider endocrinology practice runs a virtual pod of three to four: one CGM and insulin pump authorization specialist, one GLP-1 and drug authorization specialist, one A1C recall coordinator, and a half-time thyroid and procedure scheduler. Monthly cost lands around $5,500 to $7,000 at a flat $14 per hour, which is less than a single in-office prior authorization FTE in most US markets.

Practices report measurable lift in first-pass authorization rates, cleaner diabetes panel A1C distribution, and a substantial drop in new-nodule workup turnaround inside the first 90 days.